News
NICE says no to Merck Serono's Bavencio in bladder cancer
Merck Serono's Bavencio is the only checkpoint inhibitor to be approved for first-line maintenance treatment of bladder cancer in Europe, but UK cost-effectiveness agency NICE says it is to
